Vioxx (Rofecoxib): The Billion-Dollar Heartbreaker

When Pain Relief Became a Death Sentence

In the late 1990s, Merck & Co. introduced Vioxx (rofecoxib) as a revolutionary painkiller — a COX-2 inhibitor designed to relieve arthritis pain with fewer gastrointestinal side effects than traditional NSAIDs. Marketed aggressively to millions of patients, Vioxx quickly became one of the best-selling drugs in history, generating over $2.5 billion annually at its peak.

But behind the blockbuster sales figures lay a dangerous secret.

The Hidden Cardiovascular Risk

As early as 2000, Merck's own clinical trials — including the VIGOR study — showed that patients taking Vioxx had a significantly higher rate of heart attacks and strokes compared to those taking naproxen. Instead of immediately pulling the drug, Merck continued marketing it for four more years while downplaying the cardiovascular risks in communications with physicians and regulators.

In September 2004, Merck voluntarily withdrew Vioxx from the global market after a colorectal polyp prevention study (APPROVe) confirmed the cardiovascular danger. By then, an estimated 88,000 Americans had suffered heart attacks or strokes attributable to the drug, with tens of thousands of deaths.

The Litigation Avalanche

The legal fallout was staggering. Over 50,000 individual lawsuits were filed against Merck, along with class actions and state attorney general investigations. In 2007, Merck reached a $4.85 billion settlement — one of the largest pharmaceutical settlements in U.S. history — to resolve approximately 27,000 personal injury claims.

The Vioxx scandal also led to congressional hearings, a criminal plea, and a $321 million fine. It exposed systemic failures in how pharmaceutical companies disclose safety data and how the FDA monitors post-market drug safety.

Key Lessons from the Vioxx Disaster

The Vioxx case fundamentally changed pharmaceutical litigation and regulation. It demonstrated that suppressed clinical trial data, misleading marketing, and delayed safety disclosures could result in catastrophic harm to patients — and catastrophic liability for manufacturers. It also gave rise to the FDA Amendments Act of 2007, which expanded the agency's authority to require post-market safety studies and mandate Risk Evaluation and Mitigation Strategies (REMS).

For patients, Vioxx remains a sobering reminder that even widely prescribed, FDA-approved medications can carry undisclosed risks. For attorneys handling pharmaceutical litigation, it set the gold standard for large-scale mass tort proceedings.